[go: up one dir, main page]

NO20050948L - Preparater med langvarig frigivelse omfattende lamotrigin - Google Patents

Preparater med langvarig frigivelse omfattende lamotrigin

Info

Publication number
NO20050948L
NO20050948L NO20050948A NO20050948A NO20050948L NO 20050948 L NO20050948 L NO 20050948L NO 20050948 A NO20050948 A NO 20050948A NO 20050948 A NO20050948 A NO 20050948A NO 20050948 L NO20050948 L NO 20050948L
Authority
NO
Norway
Prior art keywords
lamotrigine
prolonged
release preparations
treatment
disclosed
Prior art date
Application number
NO20050948A
Other languages
English (en)
Other versions
NO334221B1 (no
Inventor
Gary Wayne Goodson
Robin Currie
Ian Richard Buxton
Myrna A Dela-Cruz
Wlodzimierz Karolak
Mehran Maleki
Vijay Mohan Iyer
Gopal Muppirala
Alan Frank Parr
Jagdev Singh Sidhu
Robert Allen Stagner
Akunuri Venkata Vijay-Kumar
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217493A external-priority patent/GB0217493D0/en
Priority claimed from GB0217492A external-priority patent/GB0217492D0/en
Priority claimed from GB0313801A external-priority patent/GB0313801D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20050948L publication Critical patent/NO20050948L/no
Publication of NO334221B1 publication Critical patent/NO334221B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet en formulering med langvarig frigivelse av lamotrigin eller et farmasøytisk akseptabelt derivat derav og fremgangsmåte for behandling og anvendelse derav.
NO20050948A 2002-07-29 2005-02-22 Formulering med langvarig frigivelse omfattende lamotrigin NO334221B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0217493A GB0217493D0 (en) 2002-07-29 2002-07-29 Novel methods of treatment
GB0217492A GB0217492D0 (en) 2002-07-29 2002-07-29 Novel method of treatment
GB0313801A GB0313801D0 (en) 2003-06-13 2003-06-13 Novel methods of treatment
PCT/EP2003/008368 WO2004012741A1 (en) 2002-07-29 2003-07-28 Sustained release formulations comprising lamotrigine

Publications (2)

Publication Number Publication Date
NO20050948L true NO20050948L (no) 2005-02-22
NO334221B1 NO334221B1 (no) 2014-01-13

Family

ID=31499035

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050948A NO334221B1 (no) 2002-07-29 2005-02-22 Formulering med langvarig frigivelse omfattende lamotrigin

Country Status (28)

Country Link
US (1) US20050032799A1 (no)
EP (1) EP1524981B1 (no)
JP (2) JP4744142B2 (no)
KR (1) KR100882707B1 (no)
CN (1) CN100363007C (no)
AR (1) AR040709A1 (no)
AT (1) ATE424827T1 (no)
AU (1) AU2003260336C1 (no)
BR (1) BRPI0313148B8 (no)
CA (1) CA2493301A1 (no)
CO (1) CO5680405A2 (no)
CY (1) CY1109119T1 (no)
DE (1) DE60326590D1 (no)
DK (1) DK1524981T3 (no)
ES (1) ES2323268T3 (no)
IL (1) IL166424A (no)
IS (1) IS2681B (no)
MA (1) MA27509A1 (no)
MX (1) MXPA05001243A (no)
MY (1) MY141049A (no)
NO (1) NO334221B1 (no)
NZ (1) NZ537885A (no)
PL (1) PL213565B1 (no)
PT (1) PT1524981E (no)
RU (1) RU2325163C2 (no)
SI (1) SI1524981T1 (no)
TW (1) TWI342213B (no)
WO (1) WO2004012741A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
WO2008109343A1 (en) * 2007-03-01 2008-09-12 Memory Pharmaceuticals Corporation Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
JP2011528666A (ja) * 2008-07-18 2011-11-24 バレアント プハルマセウトイカルス インターナショナル 放出調節製剤及びその使用方法
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CN106389381A (zh) 2009-12-02 2017-02-15 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
WO2011086568A1 (en) * 2010-01-13 2011-07-21 Accutest Research Laboratories (I) Pvt. Ltd Controlled release composition for lamotrigine
KR20140016260A (ko) * 2011-02-03 2014-02-07 루핀 리미티드 베포타스틴의 경구용 방출 조절 약제 조성물
WO2014159275A1 (en) * 2013-03-14 2014-10-02 PharmTak, Inc. Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same
CN103920134A (zh) * 2014-05-08 2014-07-16 崔韡 一种治疗儿童眩晕的缓释片及其制备方法
RU2624229C2 (ru) * 2015-12-21 2017-07-03 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с замедленным высвобождением и способ их получения
RU2613192C1 (ru) * 2016-02-18 2017-03-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с пролонгированным высвобождением
JP2020506245A (ja) * 2017-02-03 2020-02-27 ジュビラント ジェネリックス リミテッドＪｕｂｉｌａｎｔ Ｇｅｎｅｒｉｃｓ Ｌｉｍｉｔｅｄ ラモトリギン懸濁液剤形
AU2018320946B2 (en) 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
SG11202003391XA (en) * 2017-10-27 2020-05-28 Chang Gung Memorial Hospital Linkou Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
KR20210005662A (ko) * 2018-04-25 2021-01-14 뉴로센트리아, 인크. 마그네슘 트레오네이트 조성물 및 이의 용도
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
CN116942606A (zh) * 2022-04-18 2023-10-27 上海奥科达医药科技股份有限公司 拉莫三嗪悬浮液和干混悬剂的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
JPH0667828B2 (ja) * 1985-10-09 1994-08-31 日研化学株式会社 バルプロ酸ナトリウムの持続性顆粒製剤
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
ATE133331T1 (de) * 1991-11-13 1996-02-15 Glaxo Canada Vorrichtung zur kontrollierten wirkstoffreigabe
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
ATE293458T1 (de) * 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
US6046716A (en) * 1996-12-19 2000-04-04 Colorado Microdisplay, Inc. Display system having electrode modulation to alter a state of an electro-optic layer
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EP1652516A3 (en) * 1998-11-02 2006-05-17 ALZA Corporation Osmotic controlled delivery of active agents
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0024517D0 (en) * 2000-10-06 2000-11-22 Glaxo Group Ltd Use of medicaments
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine

Also Published As

Publication number Publication date
US20050032799A1 (en) 2005-02-10
DE60326590D1 (de) 2009-04-23
AU2003260336A1 (en) 2004-02-23
KR20050026054A (ko) 2005-03-14
BR0313148A (pt) 2005-07-12
BRPI0313148B1 (pt) 2019-08-20
TW200418484A (en) 2004-10-01
MA27509A1 (fr) 2005-09-01
MY141049A (en) 2010-02-25
RU2005105353A (ru) 2005-10-27
KR100882707B1 (ko) 2009-02-06
PL213565B1 (pl) 2013-03-29
CO5680405A2 (es) 2006-09-29
ES2323268T3 (es) 2009-07-10
BRPI0313148B8 (pt) 2021-05-25
JP4744142B2 (ja) 2011-08-10
ATE424827T1 (de) 2009-03-15
TWI342213B (en) 2011-05-21
IL166424A (en) 2010-12-30
CN100363007C (zh) 2008-01-23
JP2011057683A (ja) 2011-03-24
MXPA05001243A (es) 2005-06-08
CY1109119T1 (el) 2014-07-02
HK1077003A1 (en) 2006-02-03
IL166424A0 (en) 2006-01-15
WO2004012741A1 (en) 2004-02-12
PT1524981E (pt) 2009-06-17
DK1524981T3 (da) 2009-06-22
AR040709A1 (es) 2005-04-13
JP2005538113A (ja) 2005-12-15
IS7707A (is) 2005-02-23
SI1524981T1 (sl) 2009-08-31
CN1681509A (zh) 2005-10-12
IS2681B (is) 2010-09-15
CA2493301A1 (en) 2004-02-12
NZ537885A (en) 2007-11-30
RU2325163C2 (ru) 2008-05-27
AU2003260336C1 (en) 2008-05-29
NO334221B1 (no) 2014-01-13
EP1524981B1 (en) 2009-03-11
PL374982A1 (en) 2005-11-14
EP1524981A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
NO20050948L (no) Preparater med langvarig frigivelse omfattende lamotrigin
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
NO20045547L (no) Preparater og fremgangsmate for behandling av infeksjon i storfe og gris
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
CY1106199T1 (el) Παραγωγα σταυροσπορινης ως αναστολεις της δραστηριοτητας του υποδοχεα flt3 τυροσινικης κινασης
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
EP1585423A4 (en) SYSTEMS AND METHODS FOR HEALTH MONITORING AND TRANSDERMAL MEDICAMENT ISSUE
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
NO2013007I2 (no) Dapagliflozin og farmasøytisk akseptable salter derav
CY1114210T1 (el) Απο του στοματος μορφη δοσολογιας περιλαμβανουσα αναστολεα pde 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
LU91882I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
AR034343A1 (es) Combinaciones farmaceuticas
NO20051892L (no) Ny forbindelse
EP1534295A4 (en) FORMULATIONS AND METHODS OF ADMINISTRATION OF CEPHALOTAXINS, INCLUDING HOMOHARRINGTONIN
NO20021094L (no) Profylaktiske og terapeutiske medikamenter for oftalmologiske sykdommer
NO20051893L (no) Ny forbindelse
NO20022008D0 (no) Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

MK1K Patent expired